Clinical Trial Update: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating toripalimab in combination with lenvatinib and TACE as conversion therapy for potentially resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• TACE (transarterial chemoembolization) (transarterial chemoembolization)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN